Teriparatide in a patient with severe osteoporosis, hypoparathyroidism and thalassemia major
<p>β-Thalassemia Major (TM) is a form of beta-thalassemias. TM complications include, among others, osteoporosis, whose frequency, among TM patients, varies from 13.6% to 50%. The overall etiological mechanisms of TM-related osteoporosis remain unclarified. The primary approach to osteoporosis...
Saved in:
Main Authors: | Graziani A (Author), Cannito M (Author), Putti MC (Author), Camozzi V (Author) |
---|---|
Format: | Book |
Published: |
International Journal of Clinical Endocrinology and Metabolism - Peertechz Publications,
2022-12-22.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
To determine the prevelence of hypoparathyroidism in children with thalassemia major and its corelation to serum ferritin
by: Rajnesh Kumar, et al.
Published: (2022) -
Osteoporosis in Thalassemia Major
by: Pembe Hare Yiğitoğlu, et al.
Published: (2012) -
Intermittent Bi-Daily Sub-cutaneous Teriparatide Administration in Children With Hypoparathyroidism: A Single-Center Experience
by: Julie Bernardor, et al.
Published: (2021) -
The Effect of Teriparatide Treatment on Spinal Deformity Index in Severe Osteoporosis
by: Fatma Gül Ülkü Demir, et al.
Published: (2019) -
Profile of teriparatide in the management of postmenopausal osteoporosis
by: Andrea Sikon, et al.
Published: (2010)